质荷比为9348Da的肽段对肝母细胞瘤的预后价值

The Value of Peptide which m/z is 9348Da in the Prognosis Monitoring of Hepatoblastoma

通过蛋白质组学技术中的SELDI-TOF-MS检测肝母细胞瘤的血清生物学标记物,应用ELISA技术检测对比该标记物在正常健康儿童和肝母细胞瘤患儿术前、术后、不同治疗阶段及不同预后患儿不同治疗阶段血清中的含量,结果显示正常组与治愈组中含量最高,术前组、术后组、化疗组、复发组含量较低,且预后良好组多个阶段均明显高于预后不良组,提示质荷比为9 348Da的肽段对肝母细胞瘤的预后及疗效有监测作用,其含量越低,预后越差。

By screening the biological marker of hepatoblastoma by proteomic, detecting and contrasting the difference of the content in the serum of normal children, patients with hepatoblastoma, and different stages patients. We found that the content in the normal and cured patients were more than the preoperation, postoperation, chemotherapy, curation and recurrent group, as well as the content in the preoperative sera of curative group was more than the non-curative group. So we consider the peptide whose m/z is 9 348Da is useful to monitor the prognosis of hepatoblastoma.